一种用于轻度认知障碍患者认知功能的营养配方：一项安慰剂对照试验及开放标签延长期研究。

A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension.

作者信息

Remington Ruth, Lortie Jevin J, Hoffmann Heather, Page Robert, Morrell Christopher, Shea Thomas B

机构信息

Framingham State University, Framingham, MA, USA.

Knox College, Galesburg, IL, USA.

出版信息

J Alzheimers Dis. 2015;48(3):591-5. doi: 10.3233/JAD-150057.

DOI:10.3233/JAD-150057

PMID:26402075

Abstract

Thirty-four individuals with mild cognitive impairment were randomized for 6 months to a nutraceutical formulation (NF: folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) or indistinguishable placebo, followed by a 6-month open-label extension in which all individuals received NF. The NF cohort improved in the Dementia Rating Scale (DRS; effect size >0.7) and maintained baseline performance in CLOX-1. The placebo cohort did not improve in DRS and declined in CLOX-1, but during the open-label extension improved in DRS and ceased declining in CLOX-1. These findings extend prior studies of NF efficacy for individuals without cognitive impairment and with Alzheimer's disease.

摘要

34名轻度认知障碍患者被随机分为两组，一组服用营养补充剂配方（NF：叶酸、α-生育酚、维生素B12、S-腺苷甲硫氨酸、N-乙酰半胱氨酸、乙酰左旋肉碱），另一组服用难以区分的安慰剂，为期6个月，随后是为期6个月的开放标签扩展期，在此期间所有患者都服用NF。NF组在痴呆评定量表（DRS；效应大小>0.7）上有所改善，在CLOX-1测试中保持了基线表现。安慰剂组在DRS上没有改善，在CLOX-1测试中表现下降，但在开放标签扩展期，DRS有所改善，CLOX-1测试中的下降趋势停止。这些发现扩展了先前关于NF对无认知障碍和患有阿尔茨海默病个体疗效的研究。